"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical Device Network, a GlobalData owned brand.

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it the most accurate CGM sensor.2 New Dexcom G7 automated ...

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for DexCom (NasdaqGS:DXCM) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 31.36% Upside As of December 21,

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled “Legal ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled “Legal ...